Cargando…
Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use
BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549658/ https://www.ncbi.nlm.nih.gov/pubmed/36210465 http://dx.doi.org/10.1186/s13287-022-03182-7 |
_version_ | 1784805720277909504 |
---|---|
author | Clancy, Jonna Hyvärinen, Kati Ritari, Jarmo Wahlfors, Tiina Partanen, Jukka Koskela, Satu |
author_facet | Clancy, Jonna Hyvärinen, Kati Ritari, Jarmo Wahlfors, Tiina Partanen, Jukka Koskela, Satu |
author_sort | Clancy, Jonna |
collection | PubMed |
description | BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be well tolerated by those who carry at least one copy of donor HLA alleles. HLA-A-B homozygotes could be valuable for HLA-matched thrombocyte products. We evaluated the feasibility of blood donor biobank and HLA imputation for the identification of potential cell donors homozygous for HLA alleles. METHODS: We imputed HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 alleles from genotypes of 20,737 Finnish blood donors in the Blood Service Biobank. We confirmed homozygosity by sequencing HLA alleles in 30 samples and by examining 36,161 MHC-located polymorphic DNA markers. RESULTS: Three hundred and seventeen individuals (1.5%), representing 41 different haplotypes, were found to be homozygous for HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 alleles. Ten most frequent haplotypes homozygous for HLA-A to -DQB1 were HLA-compatible with 49.5%, and three most frequent homozygotes to 30.4% of the Finnish population. Ten most frequent HLA-A-B homozygotes were compatible with 75.3%, and three most frequent haplotypes to 42.6% of the Finnish population. HLA homozygotes had a low level of heterozygosity in MHC-located DNA markers, in particular in HLA haplotypes enriched in Finland. CONCLUSIONS: The present study shows that HLA imputation in a blood donor biobank of reasonable size can be used to identify HLA homozygous blood donors suitable for cell therapy, HLA-typed thrombocytes and research. The homozygotes were HLA-compatible with a large fraction of the Finnish population. Regular blood donors reported to have positive attitude to research donation appear a good option for these purposes. Differences in population frequencies of HLA haplotypes emphasize the need for population-specific collections of HLA homozygous samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03182-7. |
format | Online Article Text |
id | pubmed-9549658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95496582022-10-11 Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use Clancy, Jonna Hyvärinen, Kati Ritari, Jarmo Wahlfors, Tiina Partanen, Jukka Koskela, Satu Stem Cell Res Ther Research BACKGROUND: Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be well tolerated by those who carry at least one copy of donor HLA alleles. HLA-A-B homozygotes could be valuable for HLA-matched thrombocyte products. We evaluated the feasibility of blood donor biobank and HLA imputation for the identification of potential cell donors homozygous for HLA alleles. METHODS: We imputed HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 alleles from genotypes of 20,737 Finnish blood donors in the Blood Service Biobank. We confirmed homozygosity by sequencing HLA alleles in 30 samples and by examining 36,161 MHC-located polymorphic DNA markers. RESULTS: Three hundred and seventeen individuals (1.5%), representing 41 different haplotypes, were found to be homozygous for HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 alleles. Ten most frequent haplotypes homozygous for HLA-A to -DQB1 were HLA-compatible with 49.5%, and three most frequent homozygotes to 30.4% of the Finnish population. Ten most frequent HLA-A-B homozygotes were compatible with 75.3%, and three most frequent haplotypes to 42.6% of the Finnish population. HLA homozygotes had a low level of heterozygosity in MHC-located DNA markers, in particular in HLA haplotypes enriched in Finland. CONCLUSIONS: The present study shows that HLA imputation in a blood donor biobank of reasonable size can be used to identify HLA homozygous blood donors suitable for cell therapy, HLA-typed thrombocytes and research. The homozygotes were HLA-compatible with a large fraction of the Finnish population. Regular blood donors reported to have positive attitude to research donation appear a good option for these purposes. Differences in population frequencies of HLA haplotypes emphasize the need for population-specific collections of HLA homozygous samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03182-7. BioMed Central 2022-10-09 /pmc/articles/PMC9549658/ /pubmed/36210465 http://dx.doi.org/10.1186/s13287-022-03182-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Clancy, Jonna Hyvärinen, Kati Ritari, Jarmo Wahlfors, Tiina Partanen, Jukka Koskela, Satu Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title | Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title_full | Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title_fullStr | Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title_full_unstemmed | Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title_short | Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use |
title_sort | blood donor biobank and hla imputation as a resource for hla homozygous cells for therapeutic and research use |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549658/ https://www.ncbi.nlm.nih.gov/pubmed/36210465 http://dx.doi.org/10.1186/s13287-022-03182-7 |
work_keys_str_mv | AT clancyjonna blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse AT hyvarinenkati blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse AT ritarijarmo blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse AT wahlforstiina blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse AT partanenjukka blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse AT koskelasatu blooddonorbiobankandhlaimputationasaresourceforhlahomozygouscellsfortherapeuticandresearchuse |